每经AI快讯，博拓生物（SH 688767，收盘价：39.8元）8月28日晚间发布公告称，公司第四届第二次董 事会会议于2025年8月27日在公司会议室以现场结合通讯方式召开。会议审议了《关于2025年半年度报 告及其摘要的议案》等文件。 截至发稿，博拓生物市值为59亿元。 （记者 贾运可） 每经头条（nbdtoutiao）——世界首例基因编辑猪肺成功移植人体 对话主要参与者：距离临床应用还有 多远？ 2024年1至12月份，博拓生物的营业收入构成为：体外诊断试纸占比92.91%，其他业务占比7.09%。 ...

格隆汇8月28日丨博拓生物(688767.SH)公布2025年半年度报告，报告期内，公司实现营业收入2.03亿 元，同比下降23.91%；归属于上市公司股东的净利润1240.24万元，同比下降82.82%；归属于上市公司 股东的扣除非经常性损益的净利润683.48万元，同比下降90.25%；基本每股收益0.07元。 ...

Core Viewpoint - The company, Shuoshi Biotechnology, is implementing significant salary reductions for its top executives in response to ongoing financial challenges, including consecutive years of net losses and declining revenues [1][5][6]. Salary Adjustments - The honorary chairman, Fang Yongsheng, and the chairman and general manager, Wang Guoqiang, will have their salaries reduced by 50% starting from August 15, 2025 [2]. - Other executives, including Liu Zhonghua (40% reduction), Hu Yuanyuan (40% reduction), and Zhou Guohui (40% reduction), will also see significant salary cuts [2]. - The financial director, Meng Yuanyuan, will have a 10% salary reduction, while employee supervisors Jia Zhaoqiang and Gu Lina will see reductions of 10% and 5%, respectively [1][2]. Financial Performance - Shuoshi Biotechnology reported revenues of approximately 403 million yuan and 350 million yuan for 2023 and 2024, respectively, with corresponding net losses of approximately 374 million yuan and 2 million yuan [5]. - The company's half-year report for 2025 indicated a revenue of about 176 million yuan, a year-on-year decrease of 1.05%, and a net profit of approximately 399 million yuan, down 86.35% year-on-year [6][7]. - The decline in net profit is attributed to price pressures from national procurement policies in the in vitro diagnostics industry and changes in tax rates affecting product margins [7]. Business Overview - Shuoshi Biotechnology focuses on the research, production, and sales of in vitro diagnostic reagents and related testing instruments, expanding into in vitro testing services [8]. - The company operates an integrated business model that includes reagents, instruments, and services, supported by various modern biological technology platforms [8].

Core Viewpoint - The management team of Shuoshi Bio (SH688399) has voluntarily reduced their salaries to support the company's operational cost optimization and enhance management efficiency in response to the challenging global economic environment [1][2][3] Salary Adjustments - Honorary Chairman Fang Yongsheng and Chairman/General Manager Wang Guoqiang have their annual salaries reduced by 50% [2] - Directors Liu Zhonghua, Hu Yuanyuan, and Zhou Guohui, as well as Vice General Manager, have their salaries reduced by 40% [2] - Financial Director Meng Yuanyuan and employee supervisor Jia Zhaoqiang have their salaries reduced by 10% [2] - Employee supervisor Gu Lina has her salary reduced by 5% [2] Management's Commitment - The salary reductions reflect the management's strong confidence in the company's future and their commitment to overcoming current challenges together [1][3] - The company expresses appreciation for the management's decision and aims to continuously optimize operations and respond to market changes [3] Financial Performance - In 2024, seven executives at Shuoshi Bio have annual salaries exceeding 1 million yuan, with Fang Yongsheng earning 2.0643 million yuan and Wang Guoqiang earning 2.4399 million yuan [3] - The company's revenue for 2022, 2023, and projected for 2024 are 5.535 billion yuan, 4.03 billion yuan, and 3.5 billion yuan respectively, with net profits showing a decline [7] - The half-year report for 2025 indicates a revenue of 176 million yuan, a year-on-year decrease of 1.05%, and a net profit of 3.9926 million yuan, down 86.35% year-on-year [7]

Core Viewpoint - The company, Shuoshi Biotechnology, announced voluntary salary reductions for its board members and senior management, reflecting their commitment to navigate industry challenges and enhance long-term development [2] Group 1: Salary Adjustments - The salary reductions range from 5% to 50%, effective from August 15, 2025, with the chairman and general manager's salary reduced by 50% [2] - Specific reductions include a 40% cut for two vice presidents, a 10% cut for the financial director, and a 5% cut for one employee supervisor [2] Group 2: Financial Performance - In 2024, the company reported a revenue of 350 million yuan, a year-on-year decline of 13.29%, and a net profit loss of 2 million yuan, although this represented a significant reduction in losses compared to the previous year [3] - The company experienced a sharp decline in net profit in 2023, with a loss of 374 million yuan, a 120.45% decrease year-on-year [3][5] Group 3: R&D and Market Strategy - The company increased its R&D investment to 28.86% of revenue in 2024, focusing on product line optimization and new solutions in infectious disease prevention and cancer diagnostics [6] - Despite a 37.89% increase in overseas revenue, the overall contribution of international sales remains limited, failing to offset the decline in the domestic market [6]

8月27日晚间，硕世生物（688399）发布公告称，公司部分董事、监事及全体高级管理人员自愿提出降薪，名誉董事长房永生、董事长兼总经理王国强等8 人年薪将下调，下调幅度在5%至50%不等。 | 降薪对象 | 降薪幅度 | 降薪期限 | | --- | --- | --- | | 名誉董事长房永生先 | 年薪下调 50% | 2025年8月15日起,任名誉董事长期间 | | 生 | | | | 董事长、总经理王国 | 年薪下调 50% | 2025年8月15日起,任董事长、总经理 | | 强先生 | | 期间 | | 董事、副总经理刘中 | 年薪下调 40% | 2025年8月15日起,任董事、副总经理 | | 华先生 | | 期间 | | 董事、副总经理、童 | 年新下调 40% | 2025年8月15日起,任董事、副总经理、 | | 事会秘书胡园园女士 | | 董事会秘书期间 | | 副总经理周国辉先生 | 年新下调 40% | 2025年8月15日起,任副总经理期间 | | 财务总监孟元元女士 | 年薪下调 10% | 2025年8月15日起,任财务总监期间 | | 职工监事贾兆强先生 | 年薪下调 10 ...

Core Viewpoint - The management team of Shuoshi Biotechnology (SH688399) voluntarily decided to reduce their salaries to support the company's operational cost optimization and enhance management efficiency amid challenging global economic conditions and industry environment [1][3]. Salary Reduction Details - The salary reductions include: - Honorary Chairman Fang Yongsheng: 50% reduction starting from August 15, 2025 - Chairman and General Manager Wang Guoqiang: 50% reduction starting from August 15, 2025 - Director and Deputy General Manager Liu Zhonghua: 40% reduction starting from August 15, 2025 - Director, Deputy General Manager, and Board Secretary Hu Yuanyuan: 40% reduction starting from August 15, 2025 - Deputy General Manager Zhou Guohui: 40% reduction starting from August 15, 2025 - Chief Financial Officer Meng Yuanyuan: 10% reduction starting from August 15, 2025 - Employee Supervisor Jia Zhaoqiang: 10% reduction starting from August 15, 2025 - Employee Supervisor Gu Lina: 5% reduction starting from August 15, 2025 [2]. Company Performance and Financials - In 2023, Shuoshi Biotechnology reported a significant loss with a net profit of -374 million yuan, a 120.45% decline year-on-year [6]. - For 2024, the company is expected to continue reporting losses, with a projected revenue decline of 13.29% [6]. - The company's revenue for the first half of 2025 was 176 million yuan, a 1.05% decrease year-on-year, with a net profit of 3.99 million yuan, down 86.35% from the previous year [6]. - The decline in profitability is attributed to price pressures from national procurement in the in vitro diagnostics industry and changes in tax rates affecting gross margins [6]. Cost Management Efforts - The company is actively pursuing cost reduction and efficiency improvement measures, alongside salary adjustments, to enhance operational efficiency and market competitiveness [3]. - Sales expenses, management expenses, and R&D expenses have all decreased during the reporting period, with sales expenses at 64.25 million yuan (down 1.94%), management expenses at 31.68 million yuan (down 21.02%), and R&D expenses at 40.64 million yuan (down 13.11%) [6]. R&D Investment - The proportion of R&D investment relative to revenue was 23.15%, a decrease of 3.21 percentage points year-on-year [7].

Core Viewpoint - The management team of Shuoshi Biotechnology (SH688399) voluntarily decided to reduce their salaries to support the company's operational cost optimization and enhance management efficiency in response to the challenging global economic environment and industry conditions [1][3]. Salary Reduction Details - The honorary chairman, Fang Yongsheng, and the chairman and general manager, Wang Guoqiang, will have their annual salaries reduced by 50% starting from August 15, 2025 [2]. - Other executives, including Liu Zhonghua and Hu Tongyuan, will see a 40% salary reduction, while the financial director, Meng Yuanyuan, and employee supervisors will have reductions of 10% and 5%, respectively [2]. Company Performance and Financials - In 2023, Shuoshi Biotechnology reported a significant loss, with a net profit of -374 million yuan, a decrease of 120.45% year-on-year [6]. - The company's revenue for the first half of 2025 was 176 million yuan, down 1.05% year-on-year, with a net profit of 3.99 million yuan, reflecting an 86.35% decline compared to the previous year [6]. - The decline in profitability is attributed to price pressures from national procurement in the in vitro diagnostics industry and changes in tax rates affecting gross margins [6]. Cost Management and Operational Efficiency - The company is committed to ongoing cost reduction and efficiency improvement measures, alongside expanding market reach to enhance operational efficiency and competitiveness [3]. - Sales, management, and R&D expenses have all decreased, with sales expenses at 64.25 million yuan (down 1.94%), management expenses at 31.68 million yuan (down 21.02%), and R&D expenses at 40.64 million yuan (down 13.11%) [6]. R&D Investment - R&D investment accounted for 23.15% of the company's revenue, which is a decrease of 3.21 percentage points year-on-year [7].

Core Viewpoint - The company, Shuoshi Biotechnology, announced voluntary salary reductions by its board members and senior management to support operational cost optimization and enhance competitiveness amid challenging global economic conditions [2][4]. Group 1: Salary Reductions - The honorary chairman, Fang Yongsheng, and the chairman and general manager, Wang Guoqiang, will have their annual salaries reduced by 50% starting from August 15, 2025 [3]. - Other executives, including Liu Zhonghua and Hu Yuanyuan, will see a 40% reduction in their annual salaries, while the financial director, Meng Yuanyuan, and employee supervisors will have reductions of 10% and 5%, respectively [3]. Group 2: Company Performance - In the first half of 2025, the company reported revenue of 176 million yuan, a year-on-year decrease of 1.05%, and a net profit attributable to shareholders of 3.99 million yuan, down 86.35% year-on-year [4]. Group 3: Strategic Initiatives - The company emphasized that the salary adjustments reflect management's recognition of the company's intrinsic value and confidence in future growth prospects [4]. - In addition to salary cuts, the company plans to implement cost-reduction measures and enhance market expansion efforts to improve operational efficiency and competitiveness [4].

Core Viewpoint - The management team of Shuoshi Biotechnology has voluntarily agreed to salary reductions to support the company's operational optimization and enhance management efficiency amid ongoing financial struggles [2][3]. Salary Reduction Details - Eight senior executives, including Honorary Chairman Fang Yongsheng and Chairman & General Manager Wang Guoqiang, will see salary cuts ranging from 5% to 50%, effective from August 15, 2025 [3][4]. - The most significant reduction is a 50% cut for both Fang Yongsheng and Wang Guoqiang, while other executives will experience reductions of 40% and 10% [4]. Financial Performance - Shuoshi Biotechnology has faced consecutive years of losses, with a reported net loss of 374 million yuan in 2023, a decline of 120.45% year-on-year [7]. - For the first half of 2025, the company reported a revenue of 176 million yuan, a decrease of 1.05% compared to the previous year, and a net profit of 3.99 million yuan, down 86.35% year-on-year [7][8]. Executive Compensation - Despite the financial difficulties, seven executives had annual salaries exceeding one million yuan in 2024, with Fang Yongsheng earning 2.0643 million yuan and Wang Guoqiang earning 2.4399 million yuan [5][6]. - The company emphasizes that the salary adjustments reflect the management's commitment to the company's long-term development and recognition of its intrinsic value [4][5]. Market Position - As of August 28, the stock price of Shuoshi Biotechnology was 63.08 yuan per share, with a total market capitalization of 5.3 billion yuan [9].